Today: 21 May 2026
Ford stock price slips on First Brands supplier rescue talks as investors eye Feb. 10 earnings
28 January 2026
2 mins read

Ford stock price slips on First Brands supplier rescue talks as investors eye Feb. 10 earnings

New York, Jan 28, 2026, 10:50 (EST) — Regular session

  • Ford shares dipped roughly 0.8% after a report highlighted ongoing talks to sustain bankrupt parts supplier First Brands under Chapter 11 protection.
  • First Brands has begun scaling back operations in certain North American units and issued a warning that cash flow is tight, increasing supply-chain risks for automakers.
  • Investors are closely monitoring for signs of production hiccups and gearing up for Ford’s Feb. 10 earnings and guidance.

Ford Motor shares slipped in early trading Wednesday following reports that the automaker is negotiating to support a crucial parts supplier, highlighting how fast a bankruptcy can ripple through production lines.

The issue is pressing as First Brands Group has started scaling back segments of its North American operations and is facing cash shortages, recent reports indicate. This increases the risk of delays in shipping components that can’t be easily replaced at short notice.

Automakers have less wiggle room than they’d care to admit. Even a minor supply hiccup can cascade into production delays, overtime expenses, and rising costs—right as investors gear up for the next round of earnings, hunting for clear guidance.

Ford shares slipped 0.8% to $13.82, moving in a range from $13.78 to $13.94. General Motors shares dropped roughly 1.7%, settling at $84.87.

Ford and GM are in talks with bankrupt parts supplier First Brands about a possible financing deal to keep the company afloat during its Chapter 11 proceedings, the Financial Times reported via Reuters. The discussions reportedly involve the automakers paying upfront for parts they anticipate receiving. According to the report, a deal is near but still not guaranteed, with Ford likely carrying the most risk.

First Brands provides parts to both Detroit automakers, including windscreen wiper components for Ford’s F-150 pickup, the report said. A GM spokesperson told Reuters the company is keeping a close watch on developments and preparing contingency plans, noting that operations remain unaffected at this point.

First Brands is shutting down parts of its North American operations, including its Brake Parts, Cardone, and Autolite divisions, while keeping other units active as it searches for buyers. “Over the past several months, we explored all available options to secure funding and advance the sale process,” interim CEO Charles Moore said. https://www.reuters.com/legal/litigation/f…

The supplier sought Chapter 11 protection in September, revealing liabilities topping $10 billion; this U.S. court-supervised bankruptcy procedure allows firms to restructure without shutting down. According to Reuters, a company attorney told the court that First Brands holds roughly $190 million in cash—enough to fund operations only through January’s end.

Traders are also keeping an eye on whether any agreed supplier support leads to increased near-term working-capital demands for Ford — meaning cash flowing out sooner to secure parts arriving down the line.

But talks alone won’t solve the issue. Should lenders press for liquidation or if negotiations break down, automakers may still grapple with production delays or higher sourcing costs—even if the disruption proves short-lived.

Ford is set to release its fourth-quarter and full-year 2025 results on Tuesday, Feb. 10, at 4:05 p.m. ET. The earnings call, featuring CEO Jim Farley and CFO Sherry House, will follow at 5:00 p.m. ET. Investors will be focused on any updates regarding supplier risks, production strategies, and cost pressures.

Stock Market Today

  • Q1 Earnings Analysis: Pegasystems Lags, Appian Leads Automation Software Stocks
    May 20, 2026, 8:03 PM EDT. As Q1 earnings wrap up in the automation software sector, Pegasystems (NASDAQ:PEGA) posted a disappointing 9.6% revenue decline to $430 million, missing analyst estimates by 7.3%. Its stock dropped 11.8% post-report. Conversely, Appian (NASDAQ:APPN) showed robust growth with a 21.5% revenue increase to $202.2 million, beating expectations by 5.6%, yet its shares fell 9.2%. The sector overall saw revenues exceed consensus by 0.8%, but stocks fell 6.5% on average after earnings. Pegasystems' approach centers on AI-driven workflow automation, while Appian offers a low-code platform for complex processes. These contrasting performances highlight varied market reactions despite solid fundamental advances in automation software driven by AI and machine learning integration.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Commvault stock steadies premarket after 31% wipeout on ARR worries
Previous Story

Commvault stock steadies premarket after 31% wipeout on ARR worries

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal
Next Story

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Go toTop